Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an e... Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage. 詳細を表示
Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and...
Spyre Therapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., Oct. 4, 2024 WALTHAM, Mass., Oct. 4, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the...
Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer PR Newswire WALTHAM, Mass., Oct. 1, 2024 WALTHAM, Mass., Oct. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:...
Spyre Therapeutics to Participate in Upcoming Investor Conference PR Newswire WALTHAM, Mass., Sept. 10, 2024 WALTHAM, Mass., Sept. 10, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 5.56 | 20.4336640941 | 27.21 | 34.14 | 27.21 | 604763 | 31.35165795 | CS |
4 | 2.53 | 8.3664021164 | 30.24 | 34.14 | 26.2827 | 611352 | 29.5317334 | CS |
12 | 1.93 | 6.25810635538 | 30.84 | 34.14 | 23.31 | 492429 | 28.33156034 | CS |
26 | -1.45 | -4.23728813559 | 34.22 | 40.49 | 22.19 | 545384 | 28.64938655 | CS |
52 | 21.96 | 203.145235893 | 10.81 | 47.97 | 10.42 | 478423 | 29.34762679 | CS |
156 | 21.96 | 203.145235893 | 10.81 | 47.97 | 10.42 | 478423 | 29.34762679 | CS |
260 | 21.96 | 203.145235893 | 10.81 | 47.97 | 10.42 | 478423 | 29.34762679 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約